Korea United Pharm. Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Seoul Korea, Republic of (1987)
Status: No NME R&D (1987)

Organization Overview

First Clinical Trial
2011
NCT01841086
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Korea United Pharm. Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bronchitis (Phase 3)

Dyspepsia (Phase 3)

Nausea (Phase 3)

Postoperative Nausea and Vomiting (Phase 3)

Sinusitis (Phase 4)

Vomiting (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 11
  • # of Trial APIs: 17